Amplia Therapeutics Limited (ASX:ATX) Annual Report 2022



The latest annual report of Amplia Therapeutics Limited (ATX) was published on 31 Mar 2022. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - ATX Annual Results

Amounts in AUD

Total Revenue
1.98M
Gross Profit
1.83M
EBIT
-3.64M
Net Tangible Assets
13.91M
Net Income
-3.64M
Capital Expenditures
-14.4k

ATX Income Statement 2022 Annual Report

As per the latest Income Statement of ATX, the Net revenue increased by $449795 (29%) compared to the previous period. The operating income in 2022 decreased by $-1.30M (-56%). The net income as per the annual report was -3.64M which decreased by $-1.36M (-60%) compared to previous year.

Income Statement Report (2022/2021)

2022 2021
Total Revenue 1.98M 1.53M
Gross Profit 1.83M 1.22M
Operating Income -3.64M -2.34M
Income Before Tax -3.64M -2.28M
Net Income -3.64M -2.28M

Balance Sheet - ATX 2022 Annual Report

Read further: ATX Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Amplia Therapeutics Limited showed the company increased the cash on balance sheet by $12.76M (690%). The Net tangible assets of ATX on the balance sheet were at 13.91M which is $11.51M (479%) more than previous annual report. The total stockholder equity also increased by $11.51M (111%) compared to previous reporting period.

Balance Sheet Statement Report (2022/2021)

2022 2021
Cash 14.61M 1.85M
Total Assets 24.48M 10.88M
Long Term Debt 2.1M -
Total Liabilities 2.64M 539.13k
Total Shareholder Equity 21.85M 10.34M
Net Tangible Assets 13.91M 2.4M

Cash Flow Statement - ATX 2022 Annual Report

The 2022 annual cash flow statement of Amplia Therapeutics Limited showed that the net income decreased by $-1.36M (-60%) compared to previous reporting period. Also the capital expenditure of ATX decreased by $-9055 (-169%).

As of 2022, the total cash from investing activities was -26.64k and total cash from financing activities was 17.19M.

Cash Flow Statement Report (2022/2021)

2022 2021
Net Income -3.64M -2.28M
Capital Expenditures -14.4k -5.35k
Dividends Paid - -
Total Cash From From Investing Activities -26.64k -5.35k
Total Cash From From Financing Activities 17.19M 3.66M

Amplia Therapeutics Limited Annual Report History

Income Statement

Income Statement history of Amplia Therapeutics Limited (ASX:ATX)

31 Mar 2022 31 Mar 2021 31 Mar 2020 31 Mar 2019
Total Revenue 1.98M 1.53M 34.23k 50.47k
Cost Of Revenue 154.63k 312.01k 123.22k 155.48k
Gross Profit 1.83M 1.22M -88.99k -105k
Research Development 3.77M 2.21M 1.07M 678.42k
Selling General Administrative 1.64M 1.13M 858.89k 860.83k
Non Recurring - - - -
Other Operating Expenses - - - -
Total Operating Expenses 5.63M 3.87M 2.26M 1.94M
Operating Income -3.64M -2.34M -2.22M -1.89M
Total Other Income Expense Net -534 59.01k 3.72k 20.28k
Ebit -3.64M -2.34M -2.22M -1.89M
Interest Expense -1.15k -1.15k -1.15k -1.15k
Income Before Tax -3.64M -2.28M -2.22M -1.87M
Income Tax Expense - - - -
Minority Interest - - - -
Net Income From Continuing Ops -3.64M -2.28M -2.22M -1.87M
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income -3.64M -2.28M -2.22M -1.87M
Net Income Applicable To Common Shares -3.64M -2.28M -2.22M -1.87M

Balance Sheet Statement

Balance Sheet Statement history of Amplia Therapeutics Limited (ASX:ATX)

31 Mar 2022 31 Mar 2021 31 Mar 2020 31 Mar 2019
Cash 14.61M 1.85M 1.11M 1.24M
Net Receivables 1.84M 1M 34.23k -
Other Current Assets 47.68k 41.3k 10.89k -
Total Current Assets 16.53M 2.94M 1.18M 1.25M
Property Plant Equipment 12.91k 5.47k 797 1.6k
Intangible Assets 7.94M 7.94M 7.94M 7.94M
Total Assets 24.48M 10.88M 9.12M 9.19M
Accounts Payable 368.89k 486.68k 474.07k 394.13k
Other Current Liab 161.29k 52.45k 10.61k 10.61k
Long Term Debt 2.1M - - -
Other Liab 5.41k - - -
Total Current Liabilities 530.18k 539.13k 510.62k 526.86k
Total Liab 2.64M 539.13k 510.62k 526.86k
Common Stock 151.51M 136.55M 132.9M 130.95M
Retained Earnings -128.62M -125.21M -122.93M -120.92M
Treasury Stock -1.04M -1.01M -1.37M -1.36M
Other Stockholder Equity -1.04M -1.01M -1.37M -1.36M
Total Stockholder Equity 21.85M 10.34M 8.61M 8.66M
Net Tangible Assets 13.91M 2.4M 667.83k 726.54k

Cash Flow Statement

Cash Flow Statement history of Amplia Therapeutics Limited (ASX:ATX)

31 Mar 2022 31 Mar 2021 31 Mar 2020 31 Mar 2019
Net Income -3.64M -2.28M -2.22M -1.87M
Depreciation 3.21k 672 801 1.59k
Change To Netincome 60.7k 354.08k 205.58k 230k
Change To Account Receivables -825.43k -1.02M -58.65k 403.58k
Change To Liabilities 3.72k 28.51k -16.24k 247.44k
Total Cash From Operating Activities -4.4M -2.92M -2.09M -987.35k
Capital Expenditures -14.4k -5.35k -5.35k -3.19k
Other Cashflows From Investing Activities -12.24k -12.24k -12.24k -12.24k
Total Cashflows From Investing Activities -26.64k -5.35k -5.35k -3.19k
Net Borrowings 2.1M 2.1M 2.1M 2.1M
Other Cashflows From Financing Activities -1.18M -400.26k -191.48k -12.14k
Total Cash From Financing Activities 17.19M 3.66M 1.96M -12.14k
Effect Of Exchange Rate -187 -1.41k -2.75k 14.4k
Change In Cash 12.76M 740.29k -132.79k -988.28k
Issuance Of Stock 16.27M 4.06M 2.15M 2.15M
Dividends Paid - - - -